$GBIM Hello GMIM family. Just checking in. Still waiting on Dr. Patrick Soon to send those quarterly report to the SEC so we can see what $GBIM share price is trading.
$GBIM Just checking in here again with recent run-up in IBRX stock price. Those 163,800 shares we hold have become a lot more valuable over the past week. I continue to dream of the day they just convert out GBIM shares into IBRX shares....
$GBIM Outcomes for GBIM Shareholders
Full Acquisition by ImmunityBio (IBRX)
GBIM could be fully absorbed
Shareholders may receive IBRX shares
OR receive cash based on negotiated valuation
OR receive minimal value if valuation is low
Stock Exchange / Share Conversion
GBIM shares converted into IBRX shares at a set ratio
Cash Buyout
ImmunityBio purchases remaining minority shares
Could be at a premium, fair value, or low valuation
Remain a Controlled Subsidiary (Status Quo)
GBIM stays under ImmunityBio control
Share value remains speculative/illiquid
Asset Transfer / Internal Restructuring
Patents/IP moved within corporate structure
Limited or no direct benefit to minority shareholders
Reverse Merger or Strategic Transaction
GBIM used as a vehicle for another asset or deal
highly speculative
Dissolution / Wind-Down
If dissolved, shareholders are last in priority
Unexpected Value Unlock
IP monetization or strategic shift increases value
No current public indication of this
$IBRX $GBIM Sorry but not correct. The 2024 annual report says that IBRX discontinued research on the Tarmogen platform due to poor trial outcomes. But GBIM's other platform is Neoepitopes. Protein constructs created using yeast which IBRX is working on. The hope is that they could be part of/ inside of the hAd5 adenoviris for Covid, Lynch, but we don't know. If they are not than IBRX will maybe cancel GBIM but they have been maintaining a large plant in Colorado for 4 years where GBIM is at.
$IBRX the relationship between GlobeImmune ($GBIM) and ImmunityBio ($IBRX)
ImmunityBio (via NantCell) is the majority shareholder of GlobeImmune. Dr. Pat acquired a massive stake in 2017 to secure the Tarmogen® platform, which uses heat-inactivated yeast (S. cerevisiae) to stimulate T-cell immunity.
The Tarmogen technology is now a key pillar of the "BioShield" vaccine strategy. Unlike traditional vaccines that rely on antibodies, Tarmogens activate cellular immunity, which is essential for killing tumors and clearing chronic viral infections like HIV.
This is the "crown jewel" of the GlobeImmune portfolio. It targets the KRAS mutation, which is present in 90% of pancreatic cancers and 30-50% of colorectal and lung cancers. In 2026, this is being integrated into "basket trials" alongside Anktiva to see if Anktiva can amplify the T-cell response generated by GI-4000.
